Gland
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers (NCT05884320) | M.D. Anderson Cancer Center | 2023-07-27 |
Track Gland automatically
Every clearance here is in the API, with alerts when new ones post.